Letters were sent about cladribine (Litak and Leustat), radium-223-dichloride (Xofigo▼), and ERWINASE.
In December 2017, the following letters were sent to relevant healthcare professionals:
Cladribine (Litak and Leustat): risk of progressive multifocal leukoencephalopathy (PML)
Radium-223-dichloride (Xofigo▼): increased risk of death and fractures in a randomised clinical trial with Xofigo used in combination with abiraterone acetate and prednisolone/prednisone
Vials of ERWINASE from batch 183a, 184a and 185a* should be used with a 5-micron filter needle
Article citation: Drug Safety Update volume 11 issue 6; January 2018: 6.
Don’t include personal or financial information like your National Insurance number or credit card details.